For Years, Digital Health Had a Medicare Problem. ACCESS Changes That.
If you’ve spent any time helping digital health companies sell into the U.S. market, you know the reimbursement question is usually where excitement goes to die. “How does this get paid for?” has killed more promising products than bad clinical outcomes ever did.
That’s what makes the CMMI ACCESS Model so significant. Launching July 5, 2026, ACCESS (Advancing Chronic Care with Effective, Scalable Solutions) is the first meaningful Medicare value-based pathway purpose-built for technology-enabled chronic disease management. It’s a 10-year program. Nationwide. Voluntary. And it fundamentally changes the GTM calculus for digital health companies playing in chronic conditions.
Let me break down what this means — and why founders, investors, and health system leaders should be paying attention right now.
What ACCESS Actually Is
ACCESS tests whether digitally enabled care — including AI — can improve outcomes at lower cost for Medicare fee-for-service beneficiaries. Instead of the traditional fee-for-service model where you bill per encounter, participating organizations receive prospective monthly payments tied to performance outcomes.
The model covers four clinical tracks targeting conditions that affect more than two-thirds of Medicare beneficiaries:
Early Cardio-Kidney-Metabolic (eCKM): Hypertension, dyslipidemia, obesity/overweight with central obesity markers, and prediabetes.
Cardio-Kidney-Metabolic (CKM): Diabetes, chronic kidney disease, and atherosclerotic cardiovascular disease.
Musculoskeletal (MSK): Chronic musculoskeletal pain.
Behavioral Health (BH): Depression and anxiety.
Applications for the first performance period are due by April 1, 2026 — which means companies need to be moving on this now.
Why This Is Different From Everything Before It
We’ve had pieces of digital health reimbursement for years — RPM codes, CCM codes, telehealth waivers. But those were bolted onto fee-for-service. They reimbursed the technology or the visit, not the outcome.
ACCESS flips that model. Monthly prospective payments with performance-based adjustments means the incentive structure actually rewards what digital health is supposed to do: keep people healthier between visits, catch problems earlier, and reduce downstream costs.
The 10-year duration matters, too. This isn’t a two-year pilot that disappears. CMS is committing to a decade-long runway — the kind of policy stability that allows companies to build real business models around it, and investors to underwrite them with confidence.
The GTM Implications for Founders
If your product touches hypertension, diabetes, CKD, MSK pain, depression, or anxiety — and you’ve been selling primarily to employers or commercial payers — ACCESS opens an entirely new market. Medicare fee-for-service is the largest single payer in the country, and for chronic conditions, the patient volume is massive.
But here’s what I’d caution founders to think about carefully: ACCESS isn’t just a new billing code. It’s a new care delivery model. Participating organizations need to demonstrate technology-enabled care that produces measurable outcomes. That means your product needs to do more than collect data — it needs to drive behavior change, support clinical decision-making, and produce evidence that holds up to CMS scrutiny.
The companies best positioned are those that already have clinical evidence, can demonstrate outcomes in peer-reviewed settings, and have existing relationships with provider organizations that could serve as ACCESS participants.
What Investors Should Be Watching
For VCs and PE firms evaluating digital health portfolios, ACCESS creates a new lens for due diligence. Questions to ask:
Does this company’s product align with one of the four clinical tracks? Can they produce the outcomes data that ACCESS requires? Do they have relationships with provider organizations positioned to apply? And critically — is their technology integrated enough into clinical workflows to support a monthly prospective payment model, or are they still a standalone point solution?
Companies that can check those boxes just got significantly more valuable. Those that can’t may find the gap between “interesting technology” and “fundable business” getting wider.
Health Systems: The Clock Is Ticking
With the April 1 application deadline approaching, health systems and provider organizations need to evaluate whether ACCESS makes sense for their patient population and capabilities. The conditions covered — hypertension, diabetes, CKD, MSK pain, depression, anxiety — are the bread and butter of Medicare chronic disease management. Most systems are already spending heavily on these patients. ACCESS offers a pathway to get paid differently for managing them better.
The question for health system leaders isn’t whether these patients exist in your system. They do. The question is whether you have the technology infrastructure and clinical workflows to deliver the kind of technology-enabled care ACCESS rewards.
The Bigger Picture
ACCESS is a signal. CMS is telling the market that technology-enabled chronic disease management is no longer experimental — it’s a reimbursable care delivery model with a decade-long commitment behind it.
For an industry that has struggled to build sustainable business models around “the right thing to do,” that’s a meaningful shift. The companies, investors, and health systems that move early will have a structural advantage. The ones that wait will be playing catch-up in a market where the rules have already been written.
Applications close April 1. The first performance period starts July 5. The time to figure out your ACCESS strategy is now.
